IntelGenx Technologies Corp (IGXT)

[92662]

450 sales milestone payment should be achieved by April, 2017 and IGXT should receive $650K per agreement.

Under the terms of the agreement, SWK will pay IntelGenx $6 million at closing. In return for, (i) 100% of any and all royalties (as defined in the Edgemont Pharmaceuticals, LLC License Agreement) or similar royalty amounts received on or after April 1, 2016, (ii) 100% of the $2 million milestone payment upon Edgemont reaching annual net sales of $15 million, and (iii) 35% of all potential future milestone payments. Patent protection for Forfivo XL® in the United States expires in 2027 with an authorized generic entering the market in January 2018.